Jupiter Bio in pact with US-based GI Logics

Agencies
Posted: Monday, Jun 16, 2008 at 1114 hrs IST
Updated: Monday, Jun 16, 2008 at 1114 hrs IST

Font Size

Feedback

Discuss

GSK Pharma Q3 profit rises 7%Dr Reddy's Q2 net up 3 fold at Rs 240 cr Piramal Healthcare Q2 net up 45 pct Ranbaxy hails US court ruling on Valcyte patent

Mumbai, June 16: : Pharmaceutical firm Jupiter Bioscience on Monday said it has entered into licensing agreement with California-based GI Logics Inc for developing and marketing Diamox, a product used for eradication of H pylori bacteria.

The focus of the agreement is on the "development and sales for the use of Diamox for eradication of H pylori and for a diagnostic test for infection by and eradication of the bacterium," the company said in a filing to the Bombay Stock Exchange.

Jupiter would also focus on developing and marketing these products, the company added.

Helicobacter pylori (H pylori) is a type of bacteria and is responsible for majority of peptic ulcers, a sore on the lining of the stomach or duodenum, which is the beginning of the small intestine.

Shares of Jupiter Bioscience were trading at Rs 141.95, up 3.46 per cent on the BSE in morning trade.

Post Comments

Comments: (Limit 3,000 characters)

Name		Message
Email ID
Subject

TERMS OF USE:
The views, opinions and comments posted are your, and are not endorsed by this website. You shall be solely responsible for the comment posted here. The website reserves the right to delete, reject, or otherwise remove any views, opinions and comments posted or part thereof. You shall ensure that the comment is not inflammatory, abusive, derogatory, defamatory &/or obscene, or contain pornographic matter and/or does not constitute hate mail, or violate privacy of any person (s) or breach confidentiality or otherwise is illegal, immoral or contrary to public policy. Nor should it contain anything infringing copyright &/or intellectual property rights of any person(s).

I agree to the terms of use.